Biagio Ricciuti: Insightful discussions at Rome Lung 24
Biagio Ricciuti shared a post by Stephen Liu on X and added:
“Had a great time and insightful discussions at Rome Lung 24 reviewing biomarkers for ICI efficacy in NSCLC.
With a stellar faculty Jordi Remon, Solange Peters, Francesco Passiglia, Christian Rolfo, Tony Mok, Stephen Liu, Fred Hirsch, Federico Cappuzzo, Roberto Ferrara, Benjamin Besse and many others!”
Quoting Stephen Liu’s post:
“Dr. Biagio Ricciuti summarizes immunotherapy biomarkers at Rome Lung 24. PDL1 expression is still our best biomarker: higher the better. TMB plays a role but higher cutoffs predict better. STK11/KEAP1 predict poor outcomes with PDL1 but targeting CTLA4 can potentially overcome.”
Source: Biagio Ricciuti/X and Stephen Liu/X
Biagio Ricciuti is a thoracic oncologist at the Dana-Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School. His research interests are various aspects of lung cancer, including novel therapeutics, biomarker identification, and predictive modeling for patient outcomes. Besides being actively engaged in research, Dr. Ricciuti is involved in clinical trials and patient care.
Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023